ClinicalTrials.gg
Not yet recruitingNCT07499583Updated Oct 23, 2026

Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder

A Phase 1/2 interventional study of Psilocybin in Treatment Resistant Depression and Substance Use Disorders, sponsored by Indiana University. Not yet recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Indiana University · Phase 1/2, Interventional, and Treatment

How we know

Updated Oct 23, 2026Start date movedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant — 9 open to participants now, 14 under way, 2 of them phase 3. Psilocybin · Depressive Disorder, Treatment-Resistant.

Planned enrollment
9th of 25
50 · median 30
Started
2027
the only one that year
Phase 1/2
Only one
of the 25
Primary completion
2031-02
later than 13 of 13 live
Registered
25th of 25
by date
Lead sponsor
1 of 25
Indiana University

Among the 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant, this one is the 9th largest by planned enrollment, is the only one that started in 2027, is the only one in phase 1/2, reaches primary completion later than 13 of the 13 other live ones, and was the 25th registered.

Depressive Disorder, Treatment-Resistant

450 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 148 are open to participants now.

Browse Depressive Disorder, Treatment-Resistant studies →

Open to participants now

9 of the 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant are open now, in 6 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About psilocybin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 115 Depressive Disorder, Treatment-Resistant studies recruiting now, 27 (23%) set no upper age limit and 76 (66%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if a single dose of psilocybin (5mg Vs 10mg Vs 25mg) alongside psychotherapy is safe and can help treat treatment resistant depression (TRD) with co-occurring substance use disorder (SUD). The participant sample will be enriched for veterans and first responders. Investigators seek to answer:

  • Whether 5mgs, 10mgs and 25mgs of psilocybin are safe in individuals with co-occurring TRD and SUD
  • Whether psilocybin assisted psychotherapy will reduce substance use severity and depression symptoms
  • What neurobiological processes are associated with the effects of psilocybin assisted psychotherapy.

The researchers will compare the effects of a single dose of psilocybin (either 5mgs or 10mgs or 25mg) alongside psychotherapy on substance use severity and depression symptoms over six weeks in a sample of individuals with TRD and co-occurring SUD.

In this 14-week study, participants will:

  • Visit the clinic for two intake sessions
  • Complete seven psychotherapy sessions. This will include three sessions before psilocybin administration, an 8 to 10 hour dosing session, and three sessions following psilocybin administration
  • Complete short, repeated daily assessments for six weeks, in total, before and after psilocybin administration
  • Complete two brain scans before and after psilocybin administration
Read the detailed description

This is a double-blind randomized clinical trial to examine the safety and efficacy of a single dose of psilocybin (5mg or 10mg or 25mg) in reducing substance use severity and depression symptoms in N=50 individuals with treatment resistant depression (TRD) and co-occurring substance use disorder (SUD). The study sample will be enriched for veterans and first responders.

The study will be conducted at Goodman Hall outpatient clinic located at Indiana University, Department of Psychiatry. All participants will take part in two intake visits (one to conduct safety tests and establish eligibility, and one to collect baseline and covariate data). Subjects will then participate in three preparatory psychotherapy sessions with a certified psilocybin counselor before receiving one of three, randomly assigned, psilocybin doses during an 8 to 10 hour administration session. Following psilocybin administration, subjects will participate in three weekly integrative psychotherapy sessions. Three, two-week bursts of Ecological Momentary Assessment (EMA) will additionally be administered during weeks 1 and 2, weeks 5 and 6 and weeks 10 and 11 of study participation, to measure daily substance use patterns and depression symptoms both during stressful and non-stressful situations. A pre- and post- fMRI paradigm will additionally be conducted to determine psilocybin-related changes within and between the default mode network, the salience mode network and the central executive network, during both resting state and stress. Investigators will also explore the extent to which elevations in subjective mystical and existential experience contributes to psilocybin's therapeutic and mechanistic effects.

It is anticipated that all three doses of psilocybin will be safe and well-tolerated, and that 25mgs of psilocybin compared with 5mgs will attenuate substance use severity and depressive symptoms six weeks following administration, during both stressful and non-stressful situations. In addition, it is expected that 25mg Vs 5mg psilocybin will decrease resting state functional connectivity within the default mode network (DMN) and modulate connectivity between the DMN, salience network, central executive network, and the amygdala during stress exposure.

03

Conditions studied

  • Treatment Resistant Depression
  • Substance Use Disorders

Keywords

  • treatment resistant depression
  • substance abuse disorder
  • psilocybin assisted psychotherapy
  • stress
04

Who can participate

The criteria were revised on the registry on Oct 23, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and Women 18 years or over (veterans and first responders encouraged)
  • Meets criteria for TRD (current major depressive episode without psychotic features by the Mini-International Neuropsychiatric Interview - MINI, with failure to respond to 2 or more evidence-based anti-depressants in the current episode)
  • Meets moderate to severe use criteria for one primary substance (alcohol, cocaine, opioids/heroin, or cannabis). Moderate to severe co-use of nicotine also acceptable, as well as mild/recreational use of other substances
  • Able to read English and complete study evaluations and consent
  • In good health as verified by screening examination and medical history
  • Able to safely receive MRI

Exclusion criteria

Exclusion Criteria:

  • Exclusionary psychiatric conditions include schizophrenia, schizoaffective disorder, bipolar disorder, current post-traumatic stress disorder, or history of medically serious suicide attempt
  • Actively/imminently suicidal (QIDS-SR question 12 score >2, Hamilton Depression Scale (HAM-D) question 3 score >3, or Montgomery-Åsberg Depression Rating Scale (MADRS) question 10 >4)
  • A family history of schizophrenia or schizoaffective disorder (first- or second-degree relatives), or bipolar disorder type 1 (first degree relatives)
  • Use of selective serotonin reuptake inhibitors (SSRIs) and other medications are acceptable if dose has remained stable for 6 months and is not with psilocybin, as per the study physician
  • Any prior use of classic psychedelics, including psilocybin
  • Medical conditions that would preclude safe participation in the trial (e.g., seizure disorder, significantly impaired liver function, coronary artery disease, heart failure, history of cerebrovascular accident, severe asthma, hyperthyroidism, narrow-angle glaucoma, stenosing peptic ulcer, pyloroduodenal obstruction, symptomatic prostatic hypertrophy, or bladder-neck obstruction)
  • Sitting blood pressure below 90/50 mmHg or above 165/95 mmHg
  • evidence of any conduction abnormalities, including a Bazett's interval (QTc) of >450 msec for men and QTc >470 msec for women
  • Women who are pregnant or lactating
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Psilocybin Dose - Low

    Experimental: Participants receive a single oral dose of psilocybin 5mgs

    Drug: Psilocybin

  • Experimental
    Psilocybin Dose - Moderate

    Experimental: Participants receive a single oral dose of psilocybin 10mgs

    Drug: Psilocybin

  • Experimental
    Psilocybin Dose - High

    Experimental: Participants receive a single oral dose of psilocybin 25mgs

    Drug: Psilocybin

Interventions

  • Participants will be randomly administered a single dose of either 5mg or 10mg or 25mg psilocybin

06

What researchers measure

Primary outcomes

  1. percentage number of participants with Adverse Events (AEs)

    AEs that occur after administration of the single psilocybin dose or worsen from a pre-treatment state.

    Time frame: Weekly for 12-weeks and once during a 60-day follow-up

  2. Change in % number of positive urines

    urine toxicology screens for alcohol and substance use will be collected

    Time frame: Weekly for 12-weeks

  3. Change in % number of days spent using substances

    Self reports of alcohol and substance use, using the timeline followback (TLFB) and brief ecological momentary assessment (EMA) items

    Time frame: Weekly for 12-weeks TLFB and 5 times per day in weeks 1, 2, 5, 6, 10 & 11 (brief items)

  4. Change in severity of depression symptoms

    Self reports of depressive symptomatology, using the Quick Inventory of Depression Symptoms-Self-Report (QIDS-SR) and brief EMA items using the Positive and Negative Affect Schedule (PANAS)

    Time frame: Weekly for 12-weeks QIDS and 5 times per day in weeks 1, 2, 5, 6, 10 & 11 for PANAS

  5. Changes in plasma brain-derived neurotrophic factor (BDNF) during stress exposure

    Levels of BDNF in response to stress will be assessed during brain scanning

    Time frame: Change from baseline (week 2) to post psilocybin administration (week 5)

  6. Change in resting brain functional connectivity of the default mode network (DMN).

    Resting-state functional connectivity will be assessed using functional magnetic resonance imaging (fMRI)

    Time frame: Change from baseline (week 2) to post psilocybin administration (week 5)

Secondary outcomes

  1. Change in amount of substance consumed per occasion

    Self reports of alcohol and substance use, using the TLFB and brief EMA items

    Time frame: Weekly for 12-weeks TLFB and 5 times per day in weeks 1, 2, 5, 6, 10 & 11 (brief items)

  2. Change in number of binge episodes

    Self reports of alcohol and substance use, using the TLFB and brief EMA items

    Time frame: Weekly for 12-weeks TLFB and 5 times per day in weeks 1, 2, 5, 6, 10 & 11 (brief items)

  3. Change in craving

    Various standardized craving scales will be used to collect self-report craving data in addition to brief EMA items

    Time frame: Weekly for 12-weeks (various dependent upon participants substance of choice) and 5 times per day in weeks 1, 2, 5, 6, 10 & 11 (brief items)

  4. Change in anxiety

    The State-Trait Anxiety Inventory (STAI) will be used to collect self-report anxiety data in addition to brief momentary assessment items

    Time frame: Weekly for 12-weeks (STAI) and 5 times per day in weeks 1, 2, 5, 6, 10 & 11 (brief items)

  5. Changes in emotion regulation

    The Difficulties in Emotion Regulation Scale (DERS) will be used to collect emotion regulation data in addition to the DERS adapted for EMA

    Time frame: Change from baseline (week 2) to post psilocybin administration (weeks 5 and 10)and 5 times per day in weeks 1, 2, 5, 6, 10 & 11 (adapted DERS)

  6. Changes in brain functional connectivity during stress exposure

    functional connectivity will be assessed during stress exposure in the scanner

    Time frame: Change from baseline (week 2) to post psilocybin administration (week 5)

07

Study locations

2 sites
  • Goodman Hall, Dept of Psychiatry, Indiana University
    Indianapolis, Indiana 46202-3082, United States
  • The Stark Neuroscience Building (Goodman Hall)
    Indianapolis, Indiana 46202, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Feb 2027; primary completion for Feb 2031, 48 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: start Aug 2026 → Feb 2027 and primary completion Jan 2031 → Feb 2031.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2026
First posted
Mar 30, 2026
StartEst.
Feb 1, 2027was Aug 2026
Primary completionEst.
Feb 1, 2031was Jan 2031
CompletionEst.
Feb 1, 2031
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 1, 2026→Feb 1, 2027
Oct 23, 2026
Primary completion
Jan 1, 2031→Feb 1, 2031
Oct 23, 2026
Study completion
Feb 28, 2031→Feb 1, 2031
Oct 23, 2026
Eligibility
Maximum age 70 Years→none; 6 inclusion criteria added, 1 removed; 9 exclusion criteria added, 1 removed
What changed in the criteria
Inclusion criteria
  • RemovedVeterans or first responders ii) 18 -70 years of age iii) Meets criteria for TRD (current major depressive episode without psychotic features by the Mini-International Neuropsychiatric Interview - MINI, with failure to respond to 2 or more evidence-based anti-depressants in the current episode), iv) Meets moderate to severe use criteria for one primary substance (alcohol, cocaine, opioids/heroin, or cannabis). Moderate to severe co-use of nicotine also acceptable, as well as mild/recreational use of other substances, v) Able to read English and complete study evaluations and consent vi) In good health as verified by screening examination and medical history vii) able to safely receive MRI
  • AddedMen and Women 18 years or over (veterans and first responders encouraged)
  • AddedMeets criteria for TRD (current major depressive episode without psychotic features by the Mini-International Neuropsychiatric Interview - MINI, with failure to respond to 2 or more evidence-based anti-depressants in the current episode)
  • AddedMeets moderate to severe use criteria for one primary substance (alcohol, cocaine, opioids/heroin, or cannabis). Moderate to severe co-use of nicotine also acceptable, as well as mild/recreational use of other substances
  • AddedAble to read English and complete study evaluations and consent
  • AddedIn good health as verified by screening examination and medical history
  • AddedAble to safely receive MRI
Exclusion criteria
  • RemovedExclusionary psychiatric conditions include schizophrenia, schizoaffective disorder, bipolar disorder, current post-traumatic stress disorder, or history of medically serious suicide attempt ii) Actively/imminently suicidal (QIDS-SR question 12 score >2, Hamilton - depression scale (HAM-D) question 3 score >3, or Montgomery-Åsberg Depression Rating Scale (MADRS) question 10 >4) ii) A family history of schizophrenia or schizoaffective disorder (first- or second-degree relatives), or bipolar disorder type 1 (first degree relatives) iii) Use of selective serotonin reuptake inhibitors (SSRIs) and other medications are acceptable if dose has remained stable for 6 months, and is not contra-indicated with psilocybin, as per the study physician, Dr Conroy iii) Individuals with any prior use of classic psychedelics, including psilocybin iv) Medical conditions that would preclude safe participation in the trial (e.g., seizure disorder, significantly impaired liver function, coronary artery disease, heart failure, history of cerebrovascular accident, severe asthma, hyperthyroidism, narrow-angle glaucoma, stenosing peptic ulcer, pyloroduodenal obstruction, symptomatic prostatic hypertrophy, or bladder-neck obstruction) v) Sitting blood pressure below 90/50 mmHG or above 165/95 mmHg vi) EKG evidence of any clinically significant conduction abnormalities, including a Bazett's corrected QT interval (QTc) of >450 msec for men and QTc>470 msec for women vii) Women who are pregnant or lactatin…
  • AddedExclusionary psychiatric conditions include schizophrenia, schizoaffective disorder, bipolar disorder, current post-traumatic stress disorder, or history of medically serious suicide attempt
  • AddedActively/imminently suicidal (QIDS-SR question 12 score >2, Hamilton Depression Scale (HAM-D) question 3 score >3, or Montgomery-Åsberg Depression Rating Scale (MADRS) question 10 >4)
  • AddedA family history of schizophrenia or schizoaffective disorder (first- or second-degree relatives), or bipolar disorder type 1 (first degree relatives)
  • AddedUse of selective serotonin reuptake inhibitors (SSRIs) and other medications are acceptable if dose has remained stable for 6 months and is not contra-indicated with psilocybin, as per the study physician
  • AddedAny prior use of classic psychedelics, including psilocybin
  • AddedMedical conditions that would preclude safe participation in the trial (e.g., seizure disorder, significantly impaired liver function, coronary artery disease, heart failure, history of cerebrovascular accident, severe asthma, hyperthyroidism, narrow-angle glaucoma, stenosing peptic ulcer, pyloroduodenal obstruction, symptomatic prostatic hypertrophy, or bladder-neck obstruction)
  • AddedSitting blood pressure below 90/50 mmHg or above 165/95 mmHg
  • AddedEKG evidence of any clinically significant conduction abnormalities, including a Bazett's corrected QT interval (QTc) of >450 msec for men and QTc >470 msec for women
  • AddedWomen who are pregnant or lactating
Oct 23, 2026
Contact
Study contact's phone or email changed: s•••@iu.edu→p•••@iu.edu; h•••@iu.edu→p•••@iu.edu. See the current contact
Oct 23, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Goodman Hall, Dept of Psychiatry, Indiana University · Indianapolis, United StatesContact s•••@iu.edu→p•••@iu.eduContact h•••@iu.edu→p•••@iu.edu
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Start date Aug 1, 2026→Feb 1, 2027
    Primary completion Jan 1, 2031→Feb 1, 2031
    Study completion Feb 28, 2031→Feb 1, 2031
    Eligibility Maximum age 70 Years→none; 6 inclusion criteria added, 1 removed; 9 exclusion criteria added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedVeterans or first responders ii) 18 -70 years of age iii) Meets criteria for TRD (current major depressive episode without psychotic features by the Mini-International Neuropsychiatric Interview - MINI, with failure to respond to 2 or more evidence-based anti-depressants in the current episode), iv) Meets moderate to severe use criteria for one primary substance (alcohol, cocaine, opioids/heroin, or cannabis). Moderate to severe co-use of nicotine also acceptable, as well as mild/recreational use of other substances, v) Able to read English and complete study evaluations and consent vi) In good health as verified by screening examination and medical history vii) able to safely receive MRI
    • AddedMen and Women 18 years or over (veterans and first responders encouraged)
    • AddedMeets criteria for TRD (current major depressive episode without psychotic features by the Mini-International Neuropsychiatric Interview - MINI, with failure to respond to 2 or more evidence-based anti-depressants in the current episode)
    • AddedMeets moderate to severe use criteria for one primary substance (alcohol, cocaine, opioids/heroin, or cannabis). Moderate to severe co-use of nicotine also acceptable, as well as mild/recreational use of other substances
    • AddedAble to read English and complete study evaluations and consent
    • AddedIn good health as verified by screening examination and medical history
    • AddedAble to safely receive MRI
    Exclusion criteria
    • RemovedExclusionary psychiatric conditions include schizophrenia, schizoaffective disorder, bipolar disorder, current post-traumatic stress disorder, or history of medically serious suicide attempt ii) Actively/imminently suicidal (QIDS-SR question 12 score >2, Hamilton - depression scale (HAM-D) question 3 score >3, or Montgomery-Åsberg Depression Rating Scale (MADRS) question 10 >4) ii) A family history of schizophrenia or schizoaffective disorder (first- or second-degree relatives), or bipolar disorder type 1 (first degree relatives) iii) Use of selective serotonin reuptake inhibitors (SSRIs) and other medications are acceptable if dose has remained stable for 6 months, and is not contra-indicated with psilocybin, as per the study physician, Dr Conroy iii) Individuals with any prior use of classic psychedelics, including psilocybin iv) Medical conditions that would preclude safe participation in the trial (e.g., seizure disorder, significantly impaired liver function, coronary artery disease, heart failure, history of cerebrovascular accident, severe asthma, hyperthyroidism, narrow-angle glaucoma, stenosing peptic ulcer, pyloroduodenal obstruction, symptomatic prostatic hypertrophy, or bladder-neck obstruction) v) Sitting blood pressure below 90/50 mmHG or above 165/95 mmHg vi) EKG evidence of any clinically significant conduction abnormalities, including a Bazett's corrected QT interval (QTc) of >450 msec for men and QTc>470 msec for women vii) Women who are pregnant or lactatin…
    • AddedExclusionary psychiatric conditions include schizophrenia, schizoaffective disorder, bipolar disorder, current post-traumatic stress disorder, or history of medically serious suicide attempt
    • AddedActively/imminently suicidal (QIDS-SR question 12 score >2, Hamilton Depression Scale (HAM-D) question 3 score >3, or Montgomery-Åsberg Depression Rating Scale (MADRS) question 10 >4)
    • AddedA family history of schizophrenia or schizoaffective disorder (first- or second-degree relatives), or bipolar disorder type 1 (first degree relatives)
    • AddedUse of selective serotonin reuptake inhibitors (SSRIs) and other medications are acceptable if dose has remained stable for 6 months and is not contra-indicated with psilocybin, as per the study physician
    • AddedAny prior use of classic psychedelics, including psilocybin
    • AddedMedical conditions that would preclude safe participation in the trial (e.g., seizure disorder, significantly impaired liver function, coronary artery disease, heart failure, history of cerebrovascular accident, severe asthma, hyperthyroidism, narrow-angle glaucoma, stenosing peptic ulcer, pyloroduodenal obstruction, symptomatic prostatic hypertrophy, or bladder-neck obstruction)
    • AddedSitting blood pressure below 90/50 mmHg or above 165/95 mmHg
    • AddedEKG evidence of any clinically significant conduction abnormalities, including a Bazett's corrected QT interval (QTc) of >450 msec for men and QTc >470 msec for women
    • AddedWomen who are pregnant or lactating
    Contact Study contact's phone or email changed: s•••@iu.edu→p•••@iu.edu; h•••@iu.edu→p•••@iu.edu. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Goodman Hall, Dept of Psychiatry, Indiana University · Indianapolis, United StatesContact s•••@iu.edu→p•••@iu.eduContact h•••@iu.edu→p•••@iu.edu
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07499583
Lead sponsor
Indiana University
Responsible party
Susan K. Conroy (Assitant Professor of Psychiatry, Indiana University) — Principal investigator
First posted
Mar 30, 2026
Start date
Feb 1, 2027 (estimated)
Primary completion
Feb 1, 2031 (estimated)
Completion
Feb 1, 2031 (estimated)
Last update
Oct 23, 2026

Study contacts

Susan K Conroy, MD
Contact
psycrsch@iu.edu
317-948-5450
Helen C Fox, PhD
Contact
psycrsch@iu.edu
203-671-9643
Susan K Conroy, MD, PhD
principal investigator · Indiana University
Helen C Fox, PhD
principal investigator · Indiana University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Psilocybin

Start the discussion